FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2578-2580 June 23, 2005 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In recent months, physicians and patients have been presented with a confusing array of decisions by the Food and Drug Administration (FDA) and the pharmaceutical industry regarding the use of nonsteroidal antiinflammatory drugs (NSAIDs): Merck withdrew its cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, from the market; a closely divided FDA advisory panel recommended continuing the marketing of rofecoxib and other COX-2 inhibitors; and the FDA has requested that Pfizer suspend sales of valdecoxib in the U.S. market, contrary to the recommendation of its advisory committee (although Pfizer is planning discussions with the FDA to explore the possibility of resuming these sales). To . . . [Full Text of this Article]

Source Information

Dr. Olsen is a professor of arthritis research at the University of Texas Southwestern Medical Center, Dallas.

This article has been cited by other articles:

• Scott, P A, Kingsley, G H, Smith, C M, Choy, E H, Scott, D L (2007). Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 66: 1296-1304 [Abstract] [Full Text]  
• Roswarski, T. E., Murray, M. D. (2006). Supervision of students may protect academic physicians from cognitive bias: a study of decision making and multiple treatment alternatives in medicine.. Med Decis Making 26: 154-161 [Abstract]